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Abstract 
Background: The non‑invasive prenatal test (NIPT) is based on next generation sequencing (NGS) and is used for 
screening for fetal trisomy. However, it is time‑consuming and technically difficult. Recently, peptide nucleic acid 
(PNA) probe‑based real‑time polymerase chain reaction (RT‑PCR) was developed. This study aimed to examine the 
performance of the RT‑PCR‑based NIPT for screening of common fetal trisomies
Methods: From stored maternal plasma, RT‑PCR was performed using Patio™ NIPT Detection Kit. In melting curve 
analysis, the height of melting peaks of target chromosome and reference chromosome was calculated as a peak 
ratio. The adjusted peak ratio of 8 markers with correction factors in each target chromosome was summated and 
calculated to z‑score. The cut‑off value for each target chromosome was established for classification (low risk vs. high 
risk for trisomy) whose performance was obtained in the validation phase.
Results: 330 plasma samples from pregnant women with normal fetus and 22 trisomy cell‑line samples were used 
to establish the optimal cut‑off values for z‑score of each target chromosome. In the validation phase, 1023 sam‑
ples from pregnant women including 22 cases with fetal trisomy and 1001 cases of normal control were used. The 
RT‑PCR‑based NIPT showed 95.45% sensitivity [95% confidence interval (CI) 77.16–99.88%], 98.60% specificity (95% 
CI 97.66–99.23%), and 98.53% accuracy (95% CI 97.59–99.18%) for the identification of trisomy 21, 18, or 13. Of 1023 
samples, fifteen cases were mismatched for classification [one case as a false negative (false negative rate: 4.5%) and 
14 cases as false positives (false positive rate: 1.4%)].
Conclusion: The RT‑PCR‑based NIPT showed high sensitivity and specificity for the detection of common fetal triso‑
mies and it could be a feasible alternative to NGS‑based NIPT.
Keywords: Fetal trisomy, Prenatal diagnosis, Non‑invasive prenatal test, Real‑time polymerase chain reaction, Peptide 
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Background
Screening strategies for common fetal trisomies of chro-
mosomes 21, 18, and 13 have advanced considerably over 
the past few decades. The gold standard for fetal trisomy 
detection is karyotyping through invasive tests, such as 
amniocentesis and chorionic villus sampling. However, 
these methods carry a risk of complications for both the 
mother and the fetus.
After the discovery of cell-free fetal DNA (cffDNA) 
within maternal plasma by Lo et  al. [1], noninvasive 
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prenatal test (NIPT) is widely used as a screening test 
for aneuploidy due to its high sensitivity and specificity, 
despite the shortcomings such as placental mosacism and 
test failure [2]. Various non-invasive methods of prena-
tal screening for common fetal trisomies have been sug-
gested, usually based on the next generation sequencing 
(NGS) [3, 4]. However, such methods are often techni-
cally challenging, time-consuming, and require special-
ized equipment. Furthermore, the optimal method for 
incorporating cffDNA screening into existing programs 
continues to be debated [5, 6].
Recently, molecular techniques based on the peptide 
nucleic acid (PNA) probe-based real-time polymer-
ase chain reaction (RT-PCR) have been proposed for 
identifying chromosomal abnormalities and detecting 
genetic variation. PNA probes introduce a large differ-
ence in melting temperatures between perfectly matched 
and mismatched sequences, allowing this method to be 
widely applied in molecular biology [7–9]. For example, 
PNA probes have been used in the detection of clarithro-
mycin resistance in Helicobacter pylori and microsatellite 
instability in colorectal carcinoma [7, 10–12]. Addition-
ally, this technology only needs RT-PCR equipment, 
making it relatively easy to operate, quick, and cost-effec-
tive [13].
Therefore, in this study, we examined the performance 
of a non-invasive prenatal test (NIPT) that utilized PNA 
probe-based RT-PCR as an alternative to the conven-




In the development phase, the cut-off value for the 
z-score in the RT-PCR-based NIPT was established for 
classification (low risk vs. high risk for trisomy). For this, 
330 plasma samples from pregnant women with nor-
mal fetuses and 22 trisomy cell line samples purchased 
from the Coriell Cell Repositories (GM01137, GM01413, 
GM02504, GM02571, GM03606, GM04616, GM04617, 
GM04965, AG05121, AG11552; GM00734, GM02732, 
GM03538, GM03623, GM20912, AG07167, AG0801; 
GM00503, GM00526, GM02948, GM03330, AG12070) 
were used to establish the optimal cut-off values for the 
z-score of each target chromosome. In the validation 
phase, the performance of the screening method using 
PNA probe-based RT-PCR was validated with 1,023 
plasma samples from pregnant women including 22 cases 
with common aneuploidies and 1,001 normal control 
cases.
The stored maternal plasma samples were obtained 
from five different institutions (Seoul National Univer-
sity Hospital, Seoul Metropolitan Government Seoul 
National University Boramae Medical Center, Seoul 
Women’s Hospital, CHA Bundang Medical center, and 
Pusan National University Hospital; all in the Republic of 
Korea). These institutions prospectively collected plasma 
samples of pregnant women who gave written consent 
for their clinical information and biologic samples to be 
used for research purposes. Maternal plasma samples 
were used for PNA probe-based RT-PCR, and the clas-
sification afforded by the RT-PCR-based NIPT was com-
pared to the previously established results. Brief process 
of the RT-PCR-based NIPT is shown in Fig. 1. This study 
was approved by the Institutional Review Board and was 
conducted according to the ethical principles expressed 
in the Declaration of Helsinki.
Sample preparation
All samples were taken by venipuncture and transferred 
into an ethylenediaminetetraacetic acid (EDTA)-contain-
ing tube, and then stored at − 70 ℃ after centrifugation. 
The cell-free DNA was extracted from the stored mater-
nal plasma using a QIAamp Circulating Nucleic Acid Kit 
(Qiagen, Hilden, Germany) according to the manufactur-
er’s instructions.
Screening kit for the detection of fetal aneuploidy
A Patio™ NIPT Detection Kit (SeaSun Biomateri-
als, Daejeon, Korea) consisted of 2 × qPCR premix, 
primer & PNA probe mixture (NIPT set 1–12) and 
standard control DNA 1–3 (Reference control DNA). 
PNA probes were designed to hybridize to paralogous 
Fig. 1 Brief flowchart of the examination process. Peptide nucleic 
acid (PNA)
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sequences of the target chromosome and reference 
chromosome, which were nearly identical, differing in 
one or two nucleotides. This resulted in a difference of 
melting points between target chromosome and refer-
ence chromosome (Fig.  2). Eight paralogous sequences 
(DNA markers) and corresponding PNA probes were 
used for each target chromosome, and the PNA probes 
were fluorescently labeled with fluorescein amidite or 
hexachloro-fluorescein.
Due to a minute difference in DNA amplicons (PCR 
products) for fetal trisomy analysis, robust, highly accu-
rate, and precise methods were required. The kit included 
an additional probe that eliminated part of the total 
amplicon for maximizing analytical sensitivity. There was 
an apparent competitive relationship between the detec-
tion probe and additional probe concerning the paralo-
gous sequence in optimized conditions (ex. PCR cycles, 
time, and temperature of denaturation/annealing/exten-
sion, and probe concentration). Assuming fetal frac-
tion of 10%, the difference in the ratio between normal 
and trisomy cases was 1:1.05; however, additional probes 
could increase this difference up to tenfold (1:1.5). The 
primer and probe sequences could not be revealed due 
to the manufacturer’s (SeaSun Biomaterials) patent right.
Real‑time PCR and melting curve analysis
RT-PCR (Bio-Rad, Hercules, CA, USA) was performed in 
a final volume of 20 μL that contained 10 μL of 2 × qPCR 
PreMix, 7  μL of primer and PNA probe mixture (Patio 
™ NIPT Detection Kit, NIPT set 1–12), and 3 μL of the 
cell free DNA template. The reaction conditions for the 
amplification were 50 °C for 5 min, 95 °C for 10 min, and 
60 cycles of [95 °C for 30 s, 58 °C for 45 s, and 72 °C for 
45  s] followed by melting curve analysis. The latter was 
performed using a denaturation step of 95 °C for 5 min; 
1 min hybridization steps of 75 °C, 55 °C, and 45 °C; and 
a stepwise temperature increase from 30 to 90 °C at 1 °C/
step, with a 5 s interval between each step. The data were 
analyzed using Bio-Rad CFX Manager v3.0 software (Bio-
Rad, Hercules, CA, USA).
Interpretation of results
In the melting curve analysis, the heights of melting 
peaks of the target and reference chromosomes were 
used for peak ratio calculation, which reflected the rela-
tive ratio of the amounts of each chromosome. The 
adjusted peak ratio of eight markers with correction 
factors in each target chromosome was summated and 
expressed as z-score.
Confirmation of fetal aneuploidies
Fetal trisomies were confirmed by an invasive prenatal 
test, such as amniocentesis or chorionic villus sampling. 
The normal karyotype was either determined by the inva-
sive test or considered as normal if clinically normal phe-
notype was observed after birth.
Statistical analysis
To assess the predictive ability of the Patio™ NIPT Detec-
tion Kit, the values of sensitivity, specificity, positive pre-
dictive value, negative predictive value, and diagnostic 
accuracy with 95% CI were calculated. Comparison of the 
continuous variables was performed by using the Mann–
Whitney U test. All statistical analyses were performed 
Fig. 2 The principles of PNA probe‑based RT‑PCR combined with melting curve analysis. Peptide nucleic acid (PNA)
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by using MedCalc Statistical Software version 19.0.5 
(MedCalc Software bvba, Ostend, Belgium; https:// www. 
medca lc. org; 2019) and R version 3.6.1 (http:// www.r- 
proje ct. org). Differences were considered statistically sig-
nificant when P < 0.05.
Results
Determination of the optimal cut‑off values for the z‑score 
of each target chromosome
In the development phase, ten trisomy 21, seven trisomy 
18, and five trisomy 13 cell lines and 330 maternal plasma 
samples as normal control group were used for determin-
ing the optimal cut-off values. PNA probe-based RT-PCR 
was performed, and adjusted peak ratio of eight mark-
ers with correction factors in each target chromosome 
was summated and expressed as the z-score (Additional 
file 1: Table 1). The cut-off value of the z-score was deter-
mined to include all of the trisomy samples but exclude 
those with normal karyotype. The cut-off value was 3 for 
Down syndrome, 2 for Edward syndrome, and 1 for Patau 
syndrome.
Validation of RT‑PCR‑based NIPT performance
After determining the cut-off value, 1,023 samples were 
analyzed as a validation set, which included 22 cases with 
fetal trisomy and 1,001 cases of normal controls. Demo-
graphic details of the study group are provided in Table 1. 
The median maternal age was 33  years (30–36  years; 
interquartile range), and median gestational age at sam-
pling was 12.6  weeks (12.1–13.3  weeks; interquartile 
range). The body mass index (BMI) was calculated from 
weight and height of the subjects. The median BMI was 
21.5 (19.9–24.3; interquartile range). The 22 cases of fetal 
aneuploidy (fourteen of trisomy 21, five of trisomy 18, 
and three of trisomy 13) were confirmed by invasive tests.
Figure 3 shows z-score distributions of each fetal chro-
mosome (chromosomes 21, 18, and 13). There were 
no cases with test failure (i.e., invalid test results). The 
z-score of chromosome 21 showed significant differences 
in the distribution between normal and aneuploidy fetal 
karyotype cases (median z-score 1.12 vs. 3.72, P < 0.001). 
Among the 14 cases with fetal trisomy 21, the RT-PCR-
based NIPT classified 13 cases as high risks for trisomy 
21 (92.86% [13/14]), when the pre-established cut-off 
value (> 3) was used. The RT-PCR-based NIPT also sen-
sitively detected fetal trisomy 18 and trisomy 13 (median 
z-score in chromosome 18, − 0.38 vs. 3.36, P < 0.001; 
Table. 1 Demographic characteristics of the study cohort
Data are presented as median (interquartile range); BMI, body mass index; GA, 
gestational age
Characteristics Values
Age, years 33 (30–36) (n = 1023)
Height, cm 161.3 (158.0–165.0) (n = 1020)
Weight at sampling, kg 56.5 (51.8–63.9) (n = 1000)
BMI at sampling 21.5 (19.9–24.3) (n = 998)
GA at sampling, weeks 12.6 (12.1–13.3) (n = 1023)
Fig. 3 Z‑score distributions for each fetal aneuploidy (trisomy 21, 18, 13) with the cut‑off value
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median z-score in chromosome 13, − 0.62 vs. 5.21, 
P < 0.005). The use of a cut-off value for each chromo-
some enabled all cases of trisomies 18 and 13 to be classi-
fied as high risk for respective trisomies.
Table  2 shows the predictive performance of the 
RT-PCR-based NIPT. The values of the sensitivity to 
detect fetal trisomies 21, 18, and 13 were 92.86% (95% 
confidence interval [CI] 66.13–99.82%), 100% (95% CI 
47.82–100.00%), and 100% (95% CI 29.24–100.00%), 
respectively. The values of the specificity to detect 
fetal trisomies 21, 18, and 13 were 98.91% (95% CI 
98.06–99.46%), 99.80% (95% CI 99.29–99.98%), and 
99.90% (95% CI 99.45–100.00) respectively. Among 
1,001 euploid samples, 14 were falsely classified as high 
risk for any trisomy. Details of trisomy and misclassi-
fied cases are provided in Electronic Additional file  1: 
Tables  2 and 3, respectively. The overall classification 
showed 95.45% sensitivity (95% CI 77.16–99.88%), 
98.60% specificity (95% CI 97.66–99.23%), and 98.53% 
accuracy (95% CI 97.59–99.18%).
Superior performance of the RT‑PCR‑based NIPT compared 
to that of other methods
In our study cohort, 924 participants underwent 
conventional screening test (one participant had an 
unknown result), 51 participants underwent NGS-
based NIPT (currently commercialized), and 47 par-
ticipants initially underwent invasive diagnostic tests. 
One participant did not receive any other screening 
tests. Table  3 shows comparison of the results of the 
conventional tests with those of RT-PCR-based NIPT. 
Specificity of the RT-PCR-based NIPT was significantly 
higher than of the non-NIPT screening test but similar 
to that of the NGS-based NIPT.
Table. 2 Sensitivity and specificity of the detection of common fetal trisomies
Data in parentheses are 95% confidence intervals; LR + , positive likelihood ratio; LR-, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive 
value; NaN, not-a-number
Down syndrome Edward syndrome Patau syndrome Overall
Sensitivity, % 92.86 (66.13–99.82) 100 (47.82–100.00) 100 (29.24–100.00) 95.45 (77.16–99.88)
Specificity, % 98.91 (98.06–99.46) 99.80 (99.29–99.98) 99.90 (99.45–100.00) 98.60 (97.66–99.23)
LR + 85.18 (46.49–156.04) 509.00 (127.47–2032.43) 1020.00 (143.82–7234.10) 68.25 (40.25–115.73)
LR– 0.07 (0.01–0.48) 0.00 (0.00–NaN) 0.00 (0.00–NaN) 0.05 (0.01–0.31)
PPV, % 54.17 (32.82–74.45) 71.43 (29.04–96.33) 75.00 (19.41–99.37) 60.00 (42.11–76.13)
NPV, % 99.90 (99.44–100.00) 100.00 (99.64–100.00) 100.00 (99.64–100.00) 99.90 (99.44–100.00)
Accuracy, % 98.83 (97.96–99.39) 99.80 (99.30–99.98) 99.90 (99.46–100.00) 98.53 (97.59–99.18)
Table. 3 Comparison of the results of the conventional test with those of the RT‑PCR‑based NIPT
NIPT, non-invasive prenatal test; RT-PCR, real-time polymerase chain reaction; NGS, next generation sequencing; N/A, not applicable; NS, non-specific
a Including 2 nuchal translucency, 14 Quad tests, 905 integrated tests, and 3 sequential tests (one had a sequential test, but the result was unknown)
b 47 performed an invasive diagnostic test as the primary test while 1 patient did not undergo screening test
Non‑NIPT screening  testa (n = 924) RT‑PCR‑based NIPT (n = 924) P
Sensitivity 5/5 100% 5/5 100% (–)
Specificity 834/918 91% 905/918 99%  < 0.0001
Screening positive rate 89/924 10% 18/924 1.9%
NGS based NIPT (n = 51) RT‑PCR‑based NIPT (n = 51) P
Sensitivity 3/3 100% 3/3 100% (–)
Specificity 48/48 100% 47/48 98% NS
Screening positive rate 3/51 6% 4/51 8%
Diagnostic test or no screening  testb 
(n = 48)
RT‑PCR‑based NIPT (n = 48) P
Sensitivity N/A 12/13 92% (–)
Specificity N/A 35/35 100% (‑)
Screening positive rate N/A 12/48 25%
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Discussion
The current study demonstrated excellent performance 
of the RT-PCR-based NIPT in screening for common 
fetal trisomies. The overall performance of the NIPT 
using PNA probe-based RT-PCR in screening for fetal 
trisomies 21, 13, and 18 showed 95.45% sensitivity, 
98.60% specificity, and no test failures.
PNAs, which are DNA analogs, are artificially syn-
thesized with uncharged backbone and, therefore, have 
more favorable hybridization properties as well as chemi-
cal, thermal, and biological stability parameters [10, 14]. 
The PNA probe composed of dual-labeled (quencher 
and fluorophore) to improve the resolution of detection, 
causes a large difference in melting temperature between 
specific hybridization and partial hybridization. PNAs are 
becoming increasingly used in different molecular biol-
ogy applications [7–9], e.g., in the detection of clarithro-
mycin resistance in Helicobacter pylori or demonstration 
of microsatellite instability in colorectal carcinoma [7, 
10–12].
In obstetrics, we have reported that PNA probes could 
be used for rapid determination of aneuploidy in amni-
otic fluid samples, as an alternative to fluorescence in situ 
hybridization, quantitative fluorescence PCR, and mul-
tiplex ligation-dependent probe amplification [7]. In the 
current study, we also demonstrated that PNA probe-
based RT-PCR NIPT performed superbly in the screen-
ing for common fetal aneuploidy conditions.
The NIPT based on the analysis of cell-free maternal 
plasma DNA is an innovative approach to screening for 
common fetal aneuploidies [3, 4]. Numerous studies have 
shown that NIPT detects common fetal trisomies with 
high sensitivity and specificity. However, the NIPT anal-
yses the placental DNA, not real fetal DNA, and might 
detect vanishing twin, maternal malignancy and maternal 
mosaicism, etc. [15]. In addition, until now, most NIPT 
studies have been based on NGS and therefore, reported 
frequent test failures up to 5% of the -when cell-free DNA 
concentration or fetal fraction was low [16–19]. RT-PCR-
based NIPT can report the result with smaller amounts 
of maternal blood samples than conventional methods. 
For example, most existing NIPT methods require a 
minimum of 10 mL of maternal blood sample to perform 
the test, whereas just 6 mL is sufficient with the method 
used in our study. Both RT-PCR- and NGS-based NIPTs 
include PCR amplification of cell free DNA; however, the 
RT-PCR-based method has a single amplification step 
with fewer amplified region than the NGS-based method. 
Therefore, RT-PCR-based NIPT enables a relatively more 
stable amplification process with a smaller blood sample 
volume.
After the discovery of cffDNA, non-invasive prena-
tal testing using NGS methods has rapidly developed. 
However, the NGS approach requires expensive equip-
ment, reagents, and software, and has limited throughput 
[5]. In addition, the result turnaround time is long.
Several other techniques, e.g., identification of the 
methylated regions, or plasma microRNAs, have been 
suggested for the NIPT [20–22]. The methylated region 
approaches needed pretreatment with sodium bisulfite 
or methylation-sensitive restriction enzymes. The former 
process has a low reproducibility, and the latter process 
requires long processing. Moreover, the plasma micro-
RNAs approaches might be difficult to perform at early 
pregnant due to very low levels of microRNAs. Because 
of such limitations, these methods are not commonly 
used.
Compared with the features of the NGS-based 
approach, RT-PCR-based NIPT has rapid, easy-handling, 
and low-cost procedures for screening of common fetal 
trisomies. The RT-PCR-based NIPT provides the results 
within 6 h, i.e., much easier, and faster than other molec-
ular methods, such as NGS, which require long turna-
round time and labor-intensive experiments.
In this study, 15 out of 1,023 samples were misclassified 
(Additional file 1: Table 3). Fourteen cases were classified 
as false positives. No significant differences in the charac-
teristics between the correctly classified and falsely clas-
sified groups in normal karyotype cases were observed 
(data not shown). However, one case was misclassified 
as false negative for trisomy 21, gestational age at sam-
pling of false negative case was  12+4  weeks and BMI at 
sampling was 34.9. There may be several reasons for 
misclassification by the NIPT based on cell-free DNA, 
including confined placental or real fetal mosaicism, 
vanishing twins, maternal somatic mosaicism, maternal 
copy number variants, or undetected maternal cancer 
[23]. In addition, after visually inspecting the dotplots 
of 330 maternal plasma samples of normal fetuses and 
22 trisomy cell line samples, the cut-off value for classi-
fication was determined as the value best separating the 
two groups. However, validating this cut-off value to our 
larger dataset yielded a few overlapped samples result-
ing in false positives and negatives. To be used in clinical 
practice, more larger studies may be needed to estimate 
actual performance in real-world.
To the best of our knowledge, this is the first study that 
utilized PNA probe-based RT-PCR for a NIPT. However, 
our study has limitations in that it was a retrospective 
examination of stored maternal samples and electronic 
medical records from five different institutions. Further-
more, only pregnant women of the Asian race (mostly 
Korean) were included. Due to the retrospective study 
design, the performance of RT-PCR-based NIPT pre-
sented in the current study may not represent the real-
world data both in low risk and high risk pregnancies. 
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Therefore, additional prospective studies with larger 
study cohorts, including participants of various races, 
are needed for the validation of this NIPT in real clini-
cal practice. In addition, a comparative analysis of the 
sensitivity and cost-effectiveness of RT-PCR-based and 
NGS-based NIPTs is needed. While the NIPT only pro-
vides information on common trisomies such as trisomy 
18, 13, and 21, the first trimester screening test (FTS) 
conducted in the same period may provide additional 
information on various genetic abnormalities. There-
fore, further study is needed to compare the performance 
between NIPT and FTS for various genetic diseases. The 
novel method could technically distinguish the microde-
letion/microduplication syndrome from normal control 
to create PNA probes for targeting subchromosomes; 
however, the incidence of subchromosomal abnormality 
is very low, and the actual practicality and applicability 
of its efficacy would be difficult to prove. Therefore, it is 
necessary to extend the range of NIPTs from trisomies of 
chromosome 21, 18, and 13 to other aneuploidy condi-
tions and subchromosomal abnormalities.
Conclusion
In conclusion, the PNA probe-based RT-PCR showed 
high sensitivity and specificity for the detection of fetal 
common aneuploidies. This method could be a feasible 
alternative to the NGS in the cffDNA screening test.
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